These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 34092793)

  • 1. Associations between neurofilament light chain levels, disease activity and brain atrophy in progressive multiple sclerosis.
    Szilasiova J; Mikula P; Rosenberger J; Fedicova M; Urban P; Frigova L; Vitkova M; Gdovinova Z; Hanes J; Stevens E
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2022 Sep; 166(3):304-311. PubMed ID: 34092793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma neurofilament light chain levels are predictors of disease activity in multiple sclerosis as measured by four-domain NEDA status, including brain volume loss.
    Szilasiová J; Mikula P; Rosenberger J; Fedičová M; Gdovinová Z; Urban P; Frigová L
    Mult Scler; 2021 Nov; 27(13):2023-2030. PubMed ID: 33635154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurofilament Light Chain Levels Are Associated with Disease Activity Determined by No Evident Disease Activity in Multiple Sclerosis Patients.
    Szilasiová J; Rosenberger J; Fedičová M; Mikula P; Urban P; Gdovinová Z; Vitková M; Hanes J; Stevens E
    Eur Neurol; 2021; 84(4):272-279. PubMed ID: 34034261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Annual Plasma Neurofilament Dynamics Is a Sensitive Biomarker of Disease Activity in Patients with Multiple Sclerosis.
    Fedičová M; Mikula P; Gdovinová Z; Vitková M; Žilka N; Hanes J; Frigová L; Szilasiová J
    Medicina (Kaunas); 2023 Apr; 59(5):. PubMed ID: 37241097
    [No Abstract]   [Full Text] [Related]  

  • 5. Neurofilament light chain and MRI volume parameters as markers of neurodegeneration in multiple sclerosis.
    Filippi P; Vestenická V; Siarnik P; Sivakova M; Čopíková-Cudráková D; Belan V; Hanes J; Novák M; Kollar B; Turcani P
    Neuro Endocrinol Lett; 2020 Apr; 41(1):17-26. PubMed ID: 32338853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials.
    Leppert D; Kropshofer H; Häring DA; Dahlke F; Patil A; Meinert R; Tomic D; Kappos L; Kuhle J
    Neurology; 2022 May; 98(21):e2120-e2131. PubMed ID: 35379762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis.
    Kappos L; De Stefano N; Freedman MS; Cree BA; Radue EW; Sprenger T; Sormani MP; Smith T; Häring DA; Piani Meier D; Tomic D
    Mult Scler; 2016 Sep; 22(10):1297-305. PubMed ID: 26585439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials.
    Harris S; Comi G; Cree BAC; Arnold DL; Steinman L; Sheffield JK; Southworth H; Kappos L; Cohen JA;
    Eur J Neurol; 2021 Nov; 28(11):3722-3730. PubMed ID: 34292643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Demographic and disease-related factors impact on cerebrospinal fluid neurofilament light chain levels in multiple sclerosis.
    Zondra Revendova K; Starvaggi Cucuzza C; Manouchehrinia A; Khademi M; Bar M; Leppert D; Sandberg E; Ouellette R; Granberg T; Piehl F
    Brain Behav; 2023 Jan; 13(1):e2873. PubMed ID: 36573731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis.
    Barro C; Benkert P; Disanto G; Tsagkas C; Amann M; Naegelin Y; Leppert D; Gobbi C; Granziera C; Yaldizli Ö; Michalak Z; Wuerfel J; Kappos L; Parmar K; Kuhle J
    Brain; 2018 Aug; 141(8):2382-2391. PubMed ID: 29860296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Central nervous system atrophy predicts future dynamics of disability progression in a real-world multiple sclerosis cohort.
    Tsagkas C; Naegelin Y; Amann M; Papadopoulou A; Barro C; Chakravarty MM; Gaetano L; Wuerfel J; Kappos L; Kuhle J; Granziera C; Sprenger T; Magon S; Parmar K
    Eur J Neurol; 2021 Dec; 28(12):4153-4166. PubMed ID: 34487400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing 'No Evidence of Disease Activity' Status in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice: A Retrospective Analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) Study.
    Weinstock-Guttman B; Medin J; Khan N; Korn JR; Lathi E; Silversteen J; Calkwood J; Silva D; Zivadinov R;
    CNS Drugs; 2018 Jan; 32(1):75-84. PubMed ID: 29270772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of 2-year "No evidence of disease activity" (NEDA-3 and NEDA-4) in relapsing-remitting multiple sclerosis. A real-world study.
    Bazzurri V; Fiore A; Curti E; Tsantes E; Franceschini A; Granella F
    Mult Scler Relat Disord; 2023 Nov; 79():105015. PubMed ID: 37769430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis.
    Håkansson I; Tisell A; Cassel P; Blennow K; Zetterberg H; Lundberg P; Dahle C; Vrethem M; Ernerudh J
    J Neuroinflammation; 2018 Jul; 15(1):209. PubMed ID: 30021640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain volume loss is present in Japanese multiple sclerosis patients with no evidence of disease activity.
    Yokote H; Kamata T; Toru S; Sanjo N; Yokota T
    Neurol Sci; 2018 Oct; 39(10):1713-1716. PubMed ID: 29974307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Brain Atrophy With Disease Progression Independent of Relapse Activity in Patients With Relapsing Multiple Sclerosis.
    Cagol A; Schaedelin S; Barakovic M; Benkert P; Todea RA; Rahmanzadeh R; Galbusera R; Lu PJ; Weigel M; Melie-Garcia L; Ruberte E; Siebenborn N; Battaglini M; Radue EW; Yaldizli Ö; Oechtering J; Sinnecker T; Lorscheider J; Fischer-Barnicol B; Müller S; Achtnichts L; Vehoff J; Disanto G; Findling O; Chan A; Salmen A; Pot C; Bridel C; Zecca C; Derfuss T; Lieb JM; Remonda L; Wagner F; Vargas MI; Du Pasquier R; Lalive PH; Pravatà E; Weber J; Cattin PC; Gobbi C; Leppert D; Kappos L; Kuhle J; Granziera C
    JAMA Neurol; 2022 Jul; 79(7):682-692. PubMed ID: 35575778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early-stage volume losses in the corpus callosum and thalamus predict the progression of brain atrophy in patients with multiple sclerosis.
    Fujimori J; Nakashima I
    J Neuroimmunol; 2024 Feb; 387():578280. PubMed ID: 38171046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: A post hoc analysis of the randomized TERIKIDS trial.
    Kuhle J; Chitnis T; Banwell B; Tardieu M; Arnold DL; Rawlings AM; Geertsen SS; Lublin AL; Saubadu S; Truffinet P; Kappos L
    Mult Scler; 2023 Mar; 29(3):385-394. PubMed ID: 36632983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue damage detected by quantitative gradient echo MRI correlates with clinical progression in non-relapsing progressive MS.
    Xiang B; Brier MR; Kanthamneni M; Wen J; Snyder AZ; Yablonskiy DA; Cross AH
    Mult Scler; 2022 Sep; 28(10):1515-1525. PubMed ID: 35196933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High serum neurofilament light chain levels correlate with brain atrophy and physical disability in multiple sclerosis.
    Buchmann A; Pirpamer L; Pinter D; Voortman M; Helmlinger B; Pichler A; Maceski AM; Benkert P; Bachmaier G; Ropele S; Reindl M; Leppert D; Kuhle J; Enzinger C; Khalil M
    Eur J Neurol; 2023 May; 30(5):1389-1399. PubMed ID: 36779855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.